Efficacy and CRS profiling of bispecific T-cell engagers
Are you developing multispecifics? This case study walks through how we profile a bispecific T-cell engager end to end — efficacy, mechanism, and cytokine-release liability — using tarlatamab, a CD3×DLL3 engager for small-cell lung cancer, as the worked example. We start on DLL3-positive small-cell lung cancer cells (SHP77) against a DLL3-negative NSCLC control (A549), confirm […]
MaaT Pharma: Advancing a pipeline of novel microbiome therapies across oncology
A DC-mediated killing assay for cancer vaccines, oncolytic viruses, and immune adjuvants
Over the past five years, Explicyte has supported cancer-immunotherapy programs built on inducing or enhancing a specific anti-tumor immune response. This case study covers our capacity for the advancement of cancer vaccines (peptide-, DC-, DNA-, or RNA-based), cytokine therapies, oncolytic virus–based therapies, immune modulators such as STING agonists, and immune adjuvants. Specific tumor antigen presentation: […]
How fucoidan activates immune cells and independently stalls prostate cancer growth alongside Nivolumab
Evaluation of ADCC activity using primary NK cells and SKOV3 ovarian tumor cells
Antibody-dependent cell-mediated cytotoxicity, or ADCC, is a key immune mechanism by which antibody-coated target cells are recognized and eliminated by immune effector cells. Several cells of the innate immune system, including natural killer cells and granulocytes, express CD16, a low-affinity Fc receptor for immunoglobulins. Upon binding to the Fc region of antibodies attached to target […]
Functional evidence for an immunosuppressive role of kynurenine in cancer patients
Background Long neglected, tumor immune escape is now considered a key mechanism promoting tumor growth and immune evasion. Beyond the prototypical PD1/PDL1 axis, several additional pathways have been identified as important contributors to the immune editing process. Indoleamine 2,3-dioxygenase 1, or IDO1, is a first rate-limiting enzyme of the kynurenine pathway. This pathway has been […]
Immune Cell-Mediated Killing of H1299 Lung Cancer Cells Following Anti-CD3 Activation
The initiation of an anti-tumor immune response and the subsequent elimination of cancer cells are central mechanisms of cancer immunosurveillance. In immuno-oncology drug development, one key objective is to enhance the ability of immune effector cells to recognize, engage, and eliminate tumor cells. In this context, in vitro immune cell-mediated killing assays provide a highly […]